Exerts immunomodulatory properties by phagocyte-activating effects; acts as a lymphokine of the interleukin type; enhances oxidative metabolism of tissue macrophages, antibody-dependent cellular cytotoxicity, and natural killer cell activity.

To reduce the frequency and severity of serious infections associated with chronic granulomatous disease.

Metabolized in the liver and kidneys and excreted in the urine. Mean elimination half-life after IV infusion is 38 minutes; after SQ injection, 5.0 hours; and after IM injection, 2.9 hours. Serum concentrations peak in 7 hours after SQ injection and in 4 hours after IM injection.